King's Research Portal

DOI:

[10.1016/j.jpsychores.2018.11.013](https://doi.org/10.1016/j.jpsychores.2018.11.013)

Document Version

Peer reviewed version

[Link to publication record in King's Research Portal](#)

Citation for published version (APA):

Windgassen, S., Moss-Morris, R., Goldsmith, K., & Chalder, T. (2019). Key mechanisms of cognitive behavioural therapy in irritable bowel syndrome: the importance of gastrointestinal related cognitions, behaviours and general anxiety. *Journal of Psychosomatic Research*, 118, 73-82.
<https://doi.org/10.1016/j.jpsychores.2018.11.013>

Citing this paper

Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections.

General rights

Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the Research Portal

Take down policy

If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.

Accepted Manuscript

Key mechanisms of cognitive behavioural therapy in irritable bowel syndrome: The importance of gastrointestinal related cognitions, behaviours and general anxiety

Sula Windgassen, Rona Moss-Morris, Kimberley Goldsmith, Trudie Chalder

PII: S0022-3999(18)30516-6
DOI: <https://doi.org/10.1016/j.jpsychores.2018.11.013>
Reference: PSR 9625
To appear in: *Journal of Psychosomatic Research*
Received date: 9 May 2018
Revised date: 15 November 2018
Accepted date: 17 November 2018

Please cite this article as: Sula Windgassen, Rona Moss-Morris, Kimberley Goldsmith, Trudie Chalder , Key mechanisms of cognitive behavioural therapy in irritable bowel syndrome: The importance of gastrointestinal related cognitions, behaviours and general anxiety. *PSR* (2018), <https://doi.org/10.1016/j.jpsychores.2018.11.013>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

**Key mechanisms of cognitive behavioural therapy in irritable bowel syndrome: the importance of
gastrointestinal related cognitions, behaviours and general anxiety**

1. Dr Sula Windgassen, PhD
2. Professor Rona Moss-Morris, PhD
3. Dr Kimberley Goldsmith[§], PhD
4. Professor Trudie Chalder* [§], PhD

*Corresponding Author: Prof Trudie Chalder, Department of Psychological Medicine, Institute of
Psychiatry, King's College London, Denmark Hill, London, SE5 8AZ, United Kingdom,

Trudie.Chalder@kcl.ac.uk

Tel: +44(0)20 7848 0406

[§]Joint last authors

Abstract

Background: Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder characterised by abdominal pain and altered bowel movements. Cognitive behavioural therapy (CBT) has been shown to be effective in reducing symptom severity in IBS and enhancing quality of life/ functioning. The present study sought to identify how CBT achieves change in these outcomes.

Method:

Secondary analysis was conducted on 149 patients with irritable bowel syndrome who had been randomised to cognitive behavioural therapy plus an antispasmodic medication or antispasmodic alone. Single and sequential mediation was modelled using structural equation modelling.

Gastrointestinal (GI) related avoidance behaviour, safety behaviour, cognitions and general anxiety were included as mediators.

Results:

GI safety behaviours, cognitions and general anxiety mediated treatment effect on the outcomes of symptom severity and work and social adjustment. Avoidance behaviour was not a significant mediator for either outcome. Sequential mediation models indicated that unhelpful GI related cognitions reduced before anxiety did, and this sequential path ($R \rightarrow \text{GI related cognitions} \rightarrow \text{anxiety} \rightarrow \text{outcome}$) was significant for both symptom severity ($b=-0.22$, CI [-0.40 to -0.90], $p=.005$) and work and social adjustment ($b=-.26$, CI [-.44 to -.11], $p=.003$) where 'R' is randomisation. Reduction in GI safety behaviours also preceded reduction in anxiety. This sequence ($R \rightarrow \text{GI safety behaviours} \rightarrow \text{anxiety} \rightarrow \text{outcome}$) was significant for both symptom severity ($b=-0.11$, CI [-.24 to -.01], $p=.049$) and work and social adjustment ($b=-0.12$, CI [-.23 to -.03], $p=.03$).

Conclusion:

Results suggest that it is important for psychological treatments to target IBS specific factors for change.

Keywords

Cognitive behaviour therapy; irritable bowel syndrome; treatment mechanisms; illness related cognitions; safety behaviours; anxiety

Introduction

Irritable bowel syndrome is a functional gastrointestinal disorder characterised by abdominal pain and associated changes in bowel habits [1]. The prevalence of IBS is estimated to be between 10 and 22% in the UK [2, 3] with a similar global prevalence rate [4]. There are no physiological diagnostic markers for IBS and it has long been established as a 'biopsychosocial illness' [5, 6]. As such physiological factors such as genetics or infection interact with psychological and social factors such as unhelpful gastrointestinal (GI) related cognitions, anxiety and life stress to result in bowel symptoms and abdominal pain.

Cognitive behavioural therapy (CBT) has been shown to effectively reduce symptom severity and enhance quality of life in IBS [7-9]. However, there is not one generic CBT model or approach in IBS. A number of CBT models for IBS have been developed [10-12] utilising different cognitive and behavioural strategies to target the key mechanisms identified by the respective models. The three system's model for IBS, as based on Lang's three system's model of panic disorder [13], identifies gastrointestinal (GI) related cognitions and behaviours as key factors in maintaining symptoms [12]. Therapeutic strategies such as challenging unhelpful thinking patterns and goal setting are used to change cognitions and behaviours. More recently, an interoceptive CBT model of IBS (CBT-IE) has been developed [11]. This model posits that symptoms are maintained by GI specific anxiety and hypervigilance to symptoms [11]. Exposure based techniques (interoceptive and *in vivo*) are used in CBT-IE to reduce GI specific anxiety and hypervigilance.

Identifying Treatment Mechanisms

The term 'mechanism' refers to the processes through which treatments have effect on the desired outcome [14]. Understanding what the key mechanisms of treatment are, is important for modifying treatments so that they can more effectively target identified mechanisms of action [15]. This has the potential for improving the efficacy and efficiency of treatments. Insight into mechanisms of change in treatments can also inform the understanding of the nature of IBS. Evidence for key processes in the maintenance of IBS can be inferred from research demonstrating how treatments reduce symptom

severity through change in specific mechanistic processes [14, 16]. I.e. if treatment works by reducing unhelpful GI cognitions we can infer that these cognitions are likely maintaining factors of IBS.

Both three system's CBT and CBT-IE may be classified as 'endogenous' stress models of IBS [17]. Both identify stress-inducing processes arising specifically from IBS symptoms (e.g. GI specific cognitions, behaviours, anxiety) as key maintaining processes of IBS [17, 18]. In contrast 'exogenous' stress models of IBS postulate that symptom-exacerbating stress arising from factors external to IBS (e.g. stress or general anxiety), are central maintaining factors of IBS [17]. While there is evidence to show that anxiety exogenous to IBS may have a causal role in the onset [19] and that those with IBS have increased stress reactivity [20, 21], there is less evidence suggesting that changing such exogenous factors precede change in IBS symptoms [16]. A systematic review of treatment mechanisms in CBT for IBS suggested that across different CBT treatment protocols change in IBS-specific processes, particularly GI related cognitions, were key in reducing symptom severity and improving quality of life (QoL) [16].

Cognitive and behavioural responses have been shown to have a mechanistic role in treatment effect across CBT protocols [17, 22-25]. In CBT-IE, avoidance was shown to mediate the a reduction of symptom severity [25]. Similarly, the mechanistic role of both GI related cognitions and behaviours was demonstrated in a randomised controlled trial assessing the efficacy of a three system's CBT treatment when added to an antispasmodic versus an antispasmodic alone [22]. The data from this trial is used in the present paper. The trial recruited adults from primary and secondary care sites in South London and assessed outcomes at baseline, 1.5, 3, 6 and 12 months post-randomisation [12]. CBT plus antispasmodic medication were superior to medication alone in reducing symptom severity and improving functioning at 1.5 and 3 months follow-up [12, 26]. There was some waning of response at 6 and 12 months. The trajectories for both outcomes are illustrated in panel A and B in appendix C.

Previous mediation analysis using this data conducted sequential modelling in order to identify whether GI related cognitions or behaviours changed first in a sequence of change from treatment to the outcomes of symptom severity, work and social adjustment and anxiety [22]. Separate models were run for each outcome and GI related behaviours were assessed as one construct that included

both avoidance behaviours (e.g. avoiding foods or situations) and safety behaviours (e.g. checking stools or access to the toilet). Change in behaviour was found to precede change in cognitions for all outcomes. However, the analysis did not include mediators measured at consecutive time points, limiting inferences about causality.

The present study sought to build on the previous study and wider research to explore in more detail the order of change during therapy. Based on the endogenous models of IBS, it is hypothesized that for change in outcomes to occur, it is primarily important for GI related cognitions and behaviours to change. Change in these IBS specific processes is hypothesized to lead to reduction in general anxiety. In contrast, exogenous models would lead us to expect that general anxiety would change prior to GI related cognitive and behavioural processes, as general anxiety (or stress) is the key target for change in such treatment approaches.

The present analyses advances the analytic strategy used previously by using consecutive time points (from baseline to 12 months) to aid inferences about causality. Although the significant treatment by group effect was lost by 6 months, it has been argued that it is important to conduct mechanistic research in the absence of significant treatment effects. This allows information to be gathered about what may have been responsible for this the lack of sustained effect. For example, whether the treatment did not target the treatment mechanisms as expected [27, 28]. Given that a previous factor analysis found two factors, namely control or safety behaviours and avoidance behaviour were distinguishable, we also wanted to explore these potential mediators separately [29]. The aims of the present study were to (1) identify whether CBT produced **change in symptom severity and work and social adjustment** via a change in anxiety, cognitions, avoidance behaviours and/or safety behaviours (2) identify whether mediating effects found in cognitions and/or behaviours preceded or were preceded by change in anxiety to produce change in outcomes.

Figure 1: Mediation models tested. Anx, anxiety; Cog, GI related cognitions; Beh A, GI avoidance behaviour; Beh S, GI safety behaviour; M1, first mediator in sequence; M2, second mediator in sequence; O, outcome; R, randomisation. Models 1-4 depict simple mediation models tested. The full mediation model does not identify a direct relationship between the randomisation factor (treatment) and outcome and the partial mediation model does. Full and partial mediation models were conducted for each sequential mediation model tested. In each mediation model, baseline measures of the outcome and mediators were controlled for.

Method

Design

The present study is a secondary mediation analysis of an RCT comparing the effect of CBT plus Mebeverine with Mebeverine alone on symptom severity and WSA outcomes [12, 26]. Results indicated that the addition of CBT to mebeverine improved symptom severity and work and social adjustment up to three months after treatment compared to mebeverine alone.

Participants and procedure

Individuals aged between 16 and 50, diagnosed with IBS and meeting the Rome I diagnostic criteria of IBS were recruited from London general practices. A total of 149 participants were randomised to either receive mebeverine alone or to receive CBT in addition to mebeverine [12]. Data of one participant were completely missing, leaving 148 participants for inclusion in the mediation analysis.

CBT treatment

A CBT treatment based on Lang's three systems model [13] was developed for IBS (appendix A). The treatment included psycho-education, cognitive restructuring and behavioural techniques [12]. Psycho-education provided information about the physiology of the bowel and the brain-gut connection. Cognitive restructuring was aimed at making individuals aware of unhelpful GI-related thoughts, recognising how these affected their behaviours, and GI symptoms. Behavioural techniques involved goal setting to increase helpful behaviours such as eating regular meals, whilst reducing unhelpful behaviours. These could be avoidance behaviours such as avoiding situations that may be impacted by bowel symptoms, or safety behaviours such as taking precautionary measures like trying to force the bowels to empty before leaving the house. Techniques to manage stress and prevent relapse were also included.

Measures

Primary Outcomes

The IBS Symptom Severity Scale (IBS-SSS) measures symptom severity specific to IBS, and has been found to be sensitive to change over time [30]. The maximum score is 500, with scores <75 indicating

normal bowel function. Scores between 75-174 indicate mild IBS, 175-299 moderate IBS and scores between 300-500 indicate severe IBS. The scale has been shown to have good reliability and validity [30].

The Work and Social Adjustment Scale [31] is a validated measure of work and social adjustment (WSA)/functioning. It contains 5 items each rated 0 - 8, with a total potential score of 40. The items assess individuals' ability to engage in day-to-day tasks at work, at home, socially, with family and in relationships. It was found to be a reliable and valid measure of impaired functioning [31].

Mediators

The Cognitive Scale for Functional Bowel Disorders (CSFBD) [32] is a measure of GI related cognitions. An example questionnaire item is "my bowel symptoms make me feel out of control". The scale consists of 25 items, with a possible total score of 25 to 175 with higher scores indicating more illness-related cognitions. The measure has been demonstrated to have good reliability and validity [32].

The Hospital Anxiety and Depression Scale (HADS) [33] is a general measure of depression and anxiety. Just the anxiety subscale was used to assess general anxiety with items such as "I feel tense or wound up". This is made up of 7 items scored from 0 to 3, with a total possible score of 21. Scores of 8 and above are said to indicate anxiety [34] with good sensitivity (0.9).

The IBS Behavioural Responses Questionnaire (IBS-BRQ) [29] was used to measure GI avoidance behaviour ("I avoid going out in case I have problems with my IBS") and GI safety behaviour ("I spend more time on the toilet than I would ideally like"). Both types of behaviour are asserted to maintain anxiety in the anxiety and health anxiety literature [35]. However, the nature of each behaviour is different. One seeks to exert control over the experience of illness in some way (safety behaviours) and the other relies on withdrawing from certain activities to prevent anticipated troublesome symptoms or experiences (avoidance behaviours).

Statistical Analysis

General

The data were standardised by subtracting the mean of the given scale from each score and dividing by the standard deviation for each given time point. Standardising data reduces potential problems of multicollinearity and allows comparison of indirect effects [36]. Using Z scores in mediation has been shown to provide more accuracy in statistical tests and confidence limits, as shown in several stimulation studies [37].

It has been recommended that mediation variables are assessed for significant change prior to mediation analysis [38]. For anxiety and GI related cognitions, assessment of main effects and interactions were conducted in the previous mediation paper [12, 26] and presented again in this paper only for contextual clarity. Repeated measures ANOVAs were then conducted to assess the main effects of group and time and the interaction (time x group) on the avoidance and safety behavioural subscales of the BRQ, over the three time points included in the mediation analysis (1.5, 3 and 6 months post randomisation). This analysis allowed assessment of whether change in mediator variables occurred over time, between the treatment and control groups. Significant interactions indicate that there was a change over time, which differed between groups

Mediation models

Mediation models were fitted in the structural equation modelling (SEM) framework using Mplus version 7. SEM is advocated as an approach that allows simultaneous modelling of several variables, enabling the investigation of more complex mediation models [27, 39, 40] than would be possible by conducting a series of regressions utilising Baron & Kenny's framework [41]. Path tracing rules [42] akin to what is specified in the mediation literature were used to calculate indirect effects [40]. Bias-corrected bootstrap estimates and confidence intervals were calculated for the indirect effects as recommended for the sample size [43]. Full information maximum likelihood was used to handle missing data as utilised by MPlus software and recommended in the literature to reduce bias and conserve sensitivity of analysis [44].

All mediation models controlled for baseline measures of the mediator and outcome to account for the potential confounding of the non-randomised mediator-outcome relationship, which is widely agreed to be important [40, 45, 46]. Baseline measures of the mediator and outcome are likely to be amongst

the most important confounders [47,48] and may also provide adjustment for other related confounders not included in the model. Baseline data collected just prior to randomisation was included in the analysis for all measures, apart from GI avoidance and safety behaviours as these data were not collected at this timepoint. In these cases, data from when the participants first entered the trial (2 weeks prior to randomisation) was used.

Simple mediation models with single mediators were run first to assess whether the variables identified in the CBT model of IBS significantly mediated treatment effect on outcome (figure 1). Models were run for each potential mediating variable: anxiety, GI related cognitions, GI avoidant and GI safety behaviours. These were run separately for each outcome also.

Sequential mediation models were then run to further elucidate the relationship between cognitive and behavioural processes and anxiety. Specifically, we sought to understand whether it was necessary for cognitive and behavioural change to occur first, to produce a subsequent reduction in anxiety, ultimately leading to improved outcomes. To assess this, we compared models that had cognitive or behavioural change preceding change in anxiety, to models where change in anxiety preceded cognitive or behavioural change.

To allow for causal interpretations of mediational analyses, it is important to ensure that variables are measured in a plausible temporal sequence [40, 46, 49, 50]. In other words, to infer that treatment causes change in a mediator and that this change causes subsequent change in an outcome, the mediator should be measured at an earlier time point than the outcome. To this end, the simple mediation models included mediators measured at 1.5 months post randomisation and outcomes measured at 12 month post randomisation (figure 1). In sequential mediator models, the first mediator in the sequence was measured at 1.5 months post randomisation and the second mediator at 3 months post randomisation. Outcome measures assessed at 12 month post randomisation were also used as this was the ultimate follow up time point and there was no significant difference between outcomes at 6 months and 12 months post randomisation.

Three types of model fit criteria were used to select the best fitting mediation model. Final models were selected based on whether they had acceptable or good fit across the majority of the three types

of fit indices (absolute, incremental and information) as has previously been recommended [51-55], giving priority to the RMSEA, CFI and TLI. This method was designed to tackle the sometimes conflicting criteria and the issues with model selection uncertainty [55]. Further details of the analysis are contained in appendix B.

Results

Participants

The majority of participants met the Rome I diagnostic criteria for irritable bowel syndrome (85%). A minority of patients had normal bowel function to mild symptoms (10%), with 89 (38%) participants having moderate symptoms and 122 having severe symptoms (52%). Participants were predominantly women (82%), white British (65%) with a mean age of 33.8 years (SD 8.6). The mean baseline measures are presented in table 1 and further detailed elsewhere [12, 26].

Changes in mediating variables: Anxiety, behaviours and cognition

The line graphs in figure 2 depict change in mediator variables over the 3 time points included in the mediation analysis. The changes in anxiety and cognition were previously reported in detail [12, 26] with a summary of the results presented here. There was a significant main effect of group but not time on both anxiety and GI related cognitions, indicating that on average over the different follow-up time points anxiety and GI related cognitions were significantly lower in the CBT group than in the control group (figure 2, panels A and B).

Analysis of the behavioural subscales in the present paper found that there was a significant main effect of group on GI safety behaviours $F(1,97) = 12.81, p = .001$ with lower levels of GI safety behaviours at follow-up on average in the CBT group. The main effect of time was significant, $F(1.62, 156.76) = 4.47, p = .02$, which is likely due to the relatively large decrease between baseline and post-treatment ratings of GI safety behaviours in the CBT group. For avoidance behaviours there was no significant main effect of time $F(1.60, 154.93) = 2.49, p = .10$ or group $F(1,97) = 1.16, p = .29$ suggesting that there was no difference between the groups on average over the three time points. This may be in part due to the

difference between the two groups at baseline, with their profile plots crossing between baseline and post treatment (figure 2, panel C). There were significant group*time interaction effects for all four potential mediator variables (all $p < 0.010$), which was due to the differences in effects between baseline and the two follow-up measurements.

Table 1: Baseline measures taken at 2 weeks prior to randomisation (n=235)

Variable	Total sample (n=235)	
	Mean	Standard deviation
Symptom severity	298.2	94.7
Work and social adjustment	14.3	8.1
GI related cognitions	108.4	30.6
GI related safety behaviours	44.7	10.7
GI related avoidance behaviours	44.5	17.5
Anxiety	11.0	4.6
Depression	7.2	3.8

Figure 2: Change over time in mediator variables anxiety (panel A), GI related cognitions (panel B), avoidance (panel C) and control behaviours (panel D) between groups. 95% confidence intervals plotted for each time point.

Table 2: Mediation analysis of symptom severity & work and social adjustment scores with

	Model (+ baseline)	RMSEA [90% CI]	CFI	TLI	AIC	BIC	χ^2 GOF	Indirect effect <i>p</i>
--	-----------------------	-------------------	-----	-----	-----	-----	--------------	-----------------------------

Randomisation (R), Anxiety (A), GI related cognitions (C), GI Safety Behaviours (SB), IBS Symptom Severity Score (IBS-SSS) and Work and Social Adjustment (WSA)

Basic Mediation Models	Symptom Severity								
	1a	R->A->IBS SSS	0 [0, 0.15]	1.0	1.02	1616.5	1670.5	$\chi^2(2)=1.36$, p=.5`	
Sequential Mediation Models	2a	R->C->IBS SSS	0 [0, 0.06]	1.0	1.05	1538.8	1592.8	$\chi^2(2)=0.18$, p=.92	.005
	3a	R->AB->IBS SSS	0.041 [0, 0.17]	0.996	0.984	1594.8	1648.7	$\chi^2(2)=2.49$, p=.29	.19
	4a	R->SB->IBS SSS	0 [0, 0.15]	1.0	1.01	1616.2	1670.2	$\chi^2(2)=1.62$, p=.45	.005
	5a	R->C->A->IBS SSS*	0.070 [0, 0.14]	0.981	0.952	2111.6	2198.5	$\chi^2(6)=10.38$, p=.11	.006
Sequential Mediation Models	6a	R->A->C->IBS SSS*	0.102 [0, 0.17]	0.949	0.872	2174.0	2260.9	$\chi^2(6)=15.20$, p=.02	.01
	7a	R->SB->A->IBS SSS*	0.08 [0, 0.15]	0.976	0.939	2218.9	2305.8	$\chi^2(6)=11.17$, p=.08	.049
	8a	R->A->SB->IBS SSS	0.119 [0.05, 0.19]	0.954	0.862	2200.6	2290.5	$\chi^2(6)=15.14$, p=.009	.01
	Work and Social Adjustment								
Basic Mediation Models	1b	R->A->WSA	0.041 [0, 0.14]	0.997	0.988	1543.5	1597.4	$\chi^2(2)=2.49$, p=.29	.001
	2b	R->C->WSA	0.034 [0, 0.17]	0.998	0.993	1393.3	1447.2	$\chi^2(2)=2.34$, p=.31	.001
	3b	R->AB->WSA	0 [0, 0.10]	1.0	1.04	1542.2	1596.1	$\chi^2(2)=0.46$, p=.79	.09
	4b	R->SB->WSA	0 [0, 0.07]	1.0	1.05	1567.1	1621.0	$\chi^2(2)=0.22$, p=.90	.004
Sequential Mediation Models	5b	R->C->A->WSA*	0.151 [0.10, 0.21]	0.929	0.822	1974.8	2061.8	$\chi^2(5)=26.20$, p=0.001	.002
	6b	R->A->C->WSA *	0.160 [0.10, 0.22]	0.911	0.777	2018.6	2105.5	$\chi^2(6)=28.63$, p<.001	.003
	7b	R->SB->A->WSA *	0.096 [0.03, 0.16]	0.966	0.914	2146.3	2233.2	$\chi^2(6)=14.18$, p=.03	.03
	8b	R->A->SB->	0.115 [0.06,	0.954	0.884	2125.8	2212.7	$\chi^2(6)=17.66$, p=.007	.02

		WSA*	0.18]						
	Rows in bold indicate best fitting model in comparison of two mediation sequences; * denotes full mediation model; RMSEA, root mean square error of approximation; CFI, comparative fit index, TLI, Tucker-Lewis Index; AIC, Akaike's Information Criterion; BCC, Brown-Cudeck criteria; χ^2 GOF, Chi square goodness of fit								

Rows in bold indicate best fitting model in comparison of two mediation sequences; * denotes full mediation model; RMSEA, root mean square error of approximation; CFI, comparative fit index, TLI, Tucker-Lewis Index; AIC, Akaike's Information Criterion; BCC, Brown-Cudeck criteria; χ^2 GOF, Chi square goodness of fit

ACCEPTED MANUSCRIPT

Table 3: Direct, Indirect & Total Effects in all models

Symptom Severity			Work and social adjustment		
	b (95% CI)	p		b (95% CI)	p
R → anxiety → IBS-SSS			R → anxiety → WSA		
Group → Anxiety	-.60 (-.90, -.30)	<.001	Group → Anxiety	-.61 (-.91, -.31)	<.001
Anxiety → IBS SSS	.44 (.25, .62)	<.001	Anxiety → WSA	.57 (.41, .73)	<.001
Group → IBS SSS	-.04 (-.33, .67)	.79	Group → WSA	-.19 (-.44, .11)	.18
Group → Anxiety → IBS SSS	-.13 (-.46, .11)	.002	Group → Anxiety → WSA	-.35 (-.56, -.16)	.001
R → cognitions → IBS-SSS			R → cognitions → WSA		
Group → Cognitions	-.53 (-.79, -.26)	<.001	Group → Cognitions	-.55 (-.80, -.29)	<.001
Cognitions → IBS SSS	.45 (.23, .66)	<.001	Cognitions → WSA	.65 (.49, .80)	<.001
Group → IBS SSS	-.08 (-.37, .23)	.62	Group → WSA	-.16 (-.42, .12)	.24
Group → Cognitions → IBS SSS	-.24 (-.43, -.09)	.005	Group → Cognitions → WSA	-.36 (-.57, -.17)	.001
R → avoidance behaviours → IBS-SSS			R → avoidance behaviours → WSA		
Group → Avoidance behaviour	-.49 (-.73, -.23)	<.001	Group → Avoidance behaviour	-.50 (-.76, -.26)	<.001
Avoidance behaviour → IBS SSS	.22 (-.05, .51)	.13	Avoidance behaviour → WSA	.25 (.02, .47)	.03
Group → IBS SSS	.02 (-.36, .41)	.92	Group → WSA	-.23 (-.54, .08)	.14
Group → Avoidance behaviour → IBS SSS	-.11 (-.29, .02)	.19	Group → Avoidance behaviour → WSA	-.12 (-.30, .01)	.09
R → safety behaviours → IBS-SSS			R → safety behaviours → WSA		
Group → Safety behaviour	-.96 (-1.24, -.69)	<.001	Group → Safety behaviour	-.99 (-1.26, -.71)	<.001
Safety behaviour → IBS SSS	.34 (.13, .54)	.001	Safety behaviour → WSA	.35 (.15, .56)	.001
Group → IBS SSS	.23 (-.14, .58)	.22	Group → WSA	-.03 (-.35, .32)	.86
Group → Safety behaviour → IBS SSS	-.33 (-.57, -.11)	.005	Group → Safety behaviour → WSA	-.35 (-.60, -.14)	.004
R → cognitions → anxiety → IBS-SSS			R → cognitions → anxiety → WSA		
Group → Cognitions	-.51 (-.77, -.25)	<.001	Group → Cognitions	-.53 (-.79, -.27)	<.001
Cognitions → Anxiety	.71 (.57, .85)	<.001	Cognitions → Anxiety	.74 (.58, .88)	<.001
Anxiety → IBS SSS	.59 (.41, .79)	<.001	Anxiety → WSA	.65 (.50, .80)	<.001
Group → Cognitions → Anxiety IBS-SSS	-.21 (-.38, -.09)	.005	Group → Cognitions → Anxiety WSA	-.26 (-.44, -.11)	.002
R → safety behaviours → anxiety → IBS-SSS			R → safety behaviours → anxiety → WSA		
Group → Safety behaviour	-.96 (-1.24, -.68)	<.001	Group → Safety behaviour	-.99 (-1.27, -.70)	<.001
Safety behaviour → Anxiety	.34 (.21, .46)	<.001	Safety behaviour → Anxiety	.33 (.20, .45)	<.001
Anxiety → IBS-SSS	.34 (.05, .61)	.02	Anxiety → WSA	.35 (.13, .58)	.002
Group → Safety Behaviour → Anxiety IBS-SSS	-.11 (-.24, .01)	.049	Group → Safety Behaviour Anxiety → WSA	-.12 (-.23, .03)	.03

Symptom Severity			Work and social adjustment		
	b (95% CI)	p		b (95% CI)	p
			WSA		

Simple mediation models

The four variables of interest as mediators, GI related cognitions, avoidance behaviour, safety behaviour and anxiety were initially studied using simple mediation models.

Simple mediation models, each in turn including anxiety, GI related cognitions and GI safety behaviours, fitted the data well (table 2). Anxiety significantly mediated the effect of treatment on symptom severity ($b=-0.26$, CI [-0.46 to -0.11], $p=.004$) and WSA ($b=-0.35$, CI [-0.56 to -0.16], $p=.001$). GI related cognitions were a significant mediator of CBT treatment on symptom severity ($b=-0.24$, CI [-0.43 to -0.09], $p=.005$) and WSA (table 2). Safety behaviour was also a significant mediator for symptom severity ($b=-0.33$, CI [-0.57 to -0.11], $p=.005$) and WSA ($b=-0.35$, CI [-0.60 to -0.14], $p=.004$). Avoidance behaviour did not mediate the effect of treatment on either outcome (table 2). Figure 3 shows the standardized indirect effects with the 95% confidence intervals across the four mediators tested. The mediated effects were negative as we expected, because they are products of the negative effect of the treatment on the mediator and the positive effect of the mediator on the outcome. CBT compared to control gave a negative parameter estimate for the effect of the treatment on the mediator, i.e. the mediator values were lower (better) on average in the CBT group compared to the control group. The effect of the mediator on the outcome gave a positive effect estimate because for every standard deviation increase in the mediator (worsening), there was an increase (worsening) in the outcome. The significant indirect effects were similar sizes.

Figure 3: Standardized indirect effect sizes for each mediator variable in simple mediation models with 95% confidence intervals. A) Symptom severity outcome, B) Work and social adjustment outcome.

Sequential Mediation Models

Full and partial mediation models

Comparisons of sequences modelled as full or partial mediation models for the outcome of symptom severity showed that full mediation models fit the best for all mediation sequences (appendix E) apart from the sequence $R \rightarrow \text{anxiety} \rightarrow \text{GI safety behaviours} \rightarrow \text{symptom severity}$ (model 8a, table 2), where there was little difference in the fit of the models. Comparisons of full and partial mediation models on the WSA found that all sequences fit better as full mediation models (models 5b to 8b, table 2). While most of the differences seen in AIC and BIC between full and partial models were greater than two units, they were generally small (appendix E).

Figure 4: standardised effect sizes of the indirect effects testing in sequential mediation models with 95% confidence intervals. Panel A: outcome of symptom severity. Panel B: outcome of work and social adjustment. R, randomisation, C, GI related cognitions, A, anxiety, SB, GI Safety Behaviours, SS, symptom severity, WSA, work and social adjustment

GI related cognitions and Anxiety

In line with our hypothesis, the sequence $R \rightarrow \text{GI related cognitions} \rightarrow \text{anxiety} \rightarrow \text{symptom severity}$ (appendix D, panel A) showed the best fit to the data with a good fit according to the χ^2 GOF and the CFI model fit criteria (table 2, model 5a). The lower AIC and BIC of 61 and 57 units respectively indicated that change in GI related cognitions preceding change in anxiety was more plausible than change in anxiety preceding change in GI related cognitions. The indirect effect was significant ($b = -0.22$, CI [-0.40 to -0.90], $p = .005$) and indicated that reduction in unhelpful GI related cognitions, resulted in a reduction of anxiety and this lead to the subsequent reduction in symptom severity (table 3). The same sequence was found to have the best fit for the outcome of WSA as well (appendix D, panel B), with lower AIC and BIC criteria (table 2, model 5b). The indirect effect here was also significant ($b = -.26$, CI [-.44 to -.11], $p = .003$). For both outcomes, the path in which change in GI related cognitions preceded reductions in anxiety, had the largest standardised indirect effect compared across all sequential mediation models (figure 4).

Behaviours and Anxiety

As avoidance behaviour was not a significant mediator in the basic mediation models, this was not taken forward into a sequential model, and only GI safety behaviours were studied. Concurrent with our hypothesis, the sequence $R \rightarrow \text{GI safety behaviours} \rightarrow \text{anxiety} \rightarrow \text{symptom severity}$ fit the data best (appendix D, panel B). This had a good fit according to the CFI and χ^2 GOF and an acceptable fit according to the RMSEA and TLI (table 2, model 7a). However, the AIC and BIC provided relatively weak support for the model where anxiety preceded GI safety behaviours, conflicting somewhat with the results of the other fit indices (table 2, model 8a). On balance we proceeded with the GI safety behaviours $\rightarrow$ anxiety model, where the indirect effect was significant ($b=-0.11$, CI [-.24 to -.01], $p=.049$) with improvement (decrease) in GI safety behaviours and anxiety causing an improvement (decrease) in symptom severity (table 3).

This sequence in which safety behaviour changed before anxiety reduction, was also shown to fit the data best for WSA (appendix D, panel D). The CFI indicated good fit and the RMSEA indicated acceptable fit, however the TLI, χ^2 GOF did not indicate good model fit (table 2, model 7b). As for symptom severity, the AIC and BIC provided more support for the reverse sequence ($R \rightarrow \text{anxiety} \rightarrow \text{GI safety behaviours}$) mediation model. Having given priority to RMSEA and CFI values, we therefore took forward the mediation model with superior RMSEA and CFI values ($R \rightarrow \text{GI safety behaviours} \rightarrow \text{anxiety} \rightarrow \text{outcome}$). We found that the indirect effect was significant ($b=0.12$, CI [-.23 to -.03], $p=.03$) indicating that as mediating variables decreased, WSA also decreased (table 3).

Discussion

Our paper aimed to establish whether illness-related cognitions, avoidance and safety behaviours and anxiety were significant mediators of treatment effect on the outcomes of symptom severity and WSA. Change in GI related cognitions, GI related safety behaviours and general anxiety were found to mediate the effect of CBT on both outcomes. However, avoidance behaviour was not a significant mediator. The secondary aim of the paper was to elucidate whether GI related cognitive and behavioural change preceded changes in anxiety or vice versa. The results were supporting of endogenous models of IBS, indicating that cognitive and behavioural (safety behaviours) responses specific to IBS changed prior to a reduction in general anxiety. This sequence was found to best explain

the treatment effect on both outcomes. These results suggest that targeting change in such processes are necessary to reduce both anxiety and consequently symptom severity and impaired WSA.

Mechanisms of Treatment

The results of our basic mediation analyses provided some support for both endogenous and exogenous models of IBS. The finding that GI related cognitions and GI safety behaviours significantly mediated the treatment effect on both outcomes lends support to endogenous models of IBS. This fits with findings from previous mediation studies conducted in CBT trials for IBS, which have demonstrated the mechanistic roles of cognitions, behaviours and GI specific anxiety [16]. However, the finding that general anxiety was also a significant mediator provides some support for exogenous models of IBS. These models identify stress (or anxiety) external to IBS as a key maintaining factor of IBS symptoms and therefore important to change in psychological treatment. Furthermore, it was surprising to find that avoidance behaviour was not a significant mediator. The paths from avoidance behaviour to outcome in the simple mediation models for both outcomes were not significant, suggesting that change in avoidance behaviour was not related to outcome. In contrast, significant paths from randomisation to avoidance behaviour at 1.5 months follow up indicated that CBT, at least initially, reduced avoidance behaviours (table 3). Such findings suggest that change in avoidance does not result in reductions in symptom severity or enhanced functioning.

A recent study assessing the mediating properties of avoidance behaviour, GI specific anxiety, self-efficacy and non-reactivity in CBT-IE compared to CBT without exposure (CBTWE) [25] could explain this finding. This study found that both avoidance behaviour and GI specific anxiety mediated the additional benefit of CBT-IE compared to CBTWE. It could be that in a treatment protocol that utilises more exposure-based techniques to target GI specific anxiety and hypervigilance, avoidance behaviour has more of a mechanistic role. Furthermore, moderated mediation analysis indicated that the mediated effect of avoidance was larger for participants who had high avoidance at baseline. This too offers an explanation for our results: in the absence of assessing moderated mediation, our analysis may not have detected avoidance behaviour as a mediator for a portion of the sample. Alternatively,

our overall sample may not have had sufficiently high baseline avoidance for this to be a significant mediator. Other reasons for this finding are considered further under limitations.

Our results demonstrate the importance of GI safety behaviours in the maintenance of symptoms and disruption to work and social functioning in IBS. Safety behaviours, such as excessive straining on the toilet or the use of medications to prevent symptoms, have been shown to disrupt bowel functioning and motility [56, 57]. Furthermore, individuals with IBS have reported that engaging in behaviours such as taking preventative medication and wearing protective underwear has a substantial impact on their daily lives [58, 59]. These results highlight that changing such behaviours is an important component of therapy. While some CBT protocols target a reduction of endogenous stress and focus on changing these symptom-specific behaviours, other protocols focus primarily on reducing exogenous stress and may not target safety behaviours.

The sequential models in both the previous mediation study using this data and the present study demonstrate that a three system's CBT treatment is effective in changing GI related cognitions and safety behaviours. The previous results indicated that behaviour change preceded cognitive change [22], suggesting behaviour change may facilitate the modification of cognitions. The present results demonstrate that GI specific cognitive and behavioural change precedes reduction in general anxiety. This fits with previous research in anxiety disorders and health anxiety, which has suggested that targeting the use of safety behaviours is necessary for the reduction of anxiety [35, 60, 61] and improving illness trajectories [62].

Together, these results provide further support for endogenous models of IBS. As IBS specific responses are shown to be of primary importance for changing outcomes we may consequently infer that these are key maintaining processes in IBS. In contrast, if IBS was primarily maintained by stress/anxiety external to IBS (e.g. general anxiety, life events) we may expect treatment to operate primarily by reducing general anxiety. To better assess the mechanistic value of external (or general) stress/anxiety versus IBS-specific stress (or GI related cognitive, behavioural and affective responses), a parallel mediator model could be used to quantify the mediating effects of each type of mediator.

Limitations

The present study did not collect a measure of GI specific anxiety, such as that measured by the visceral sensitivity index [63]. Consequently, we were not able to compare the mediating effect of general versus IBS-specific anxiety. The dichotomy between endogenous and exogenous stress in IBS may also be inadequate, as stress can be internal and external to IBS within the same individual.

It is recommended that mediators are measured at least once during treatment [14]. However, assessments in the original trial were only taken post treatment (aside from pre-treatment measures). Therefore, the mediational change occurred after treatment had finished. The mediational processes following treatment may differ to those that occur during treatment. Furthermore, there is a large time difference between the mediator measured at 1.5 and 3 months and the outcome at 12 months. Future studies should aim to include measurements at closer intervals for the purpose of assessing mediation [14] as has been conducted in previous mediation studies in IBS [17, 25].

Our analysis was conducted in the context of a waning treatment effect at the 12 month follow up in order to preserve temporal sequencing of variables [12]. Future mediational studies with similar follow up periods are needed to ascertain whether the results are replicated when the treatment effect is still observed. Nevertheless, assessing mediation in the context of no treatment effect is now widely considered valid and important [45, 46, 64]. It allows us to gather information about where in the theoretical mediation pathway treatment fails. This can help us to refine and improve treatments. The treatment in the present study had a significant effect up until the 3 month follow up. The decline in treatment effect may be attributable to the lack of mechanistic effect found in avoidance behaviour. This has previously been found to significantly mediate the treatment effect of CBT-IE in IBS [25]. Although in the present study avoidance behaviour was changed by treatment, it may be that the reduction in such behaviour was not sufficient to sustain the efficacy of the treatment effect at 12 months. It may be that the inclusion of more interoceptive exposure techniques as used in CBT-IE may be beneficial to the long-term effects of treatment by increasing the magnitude of treatment effect on avoidance behaviour reduction.

The final models with best fit were the full mediation models, which may in part be due to the lack of a sustained treatment effect i.e. there were no direct effects of treatment on outcome, yet there were significant indirect effects. It is, however, unlikely that our models included all possible mediators (such as GI specific anxiety). Future analysis would ideally include all hypothesised mediators in a model. Our study was also limited by a relatively small sample size, which may increase the probability of type II error [43].

Finally, IBS is a heterogeneous population with varying degrees of symptom severity, impairment and psychosocial impact [65, 66]. The two moderated mediation studies conducted to date have indicated that mechanisms of change may differ based on different patient characteristics at baseline [25, 67]. Our analysis was not designed to assess this and therefore may provide an incomplete picture of treatment mechanisms across the IBS population.

Strengths

The present study used robust methodology to study the mediation effects of CBT in IBS. Unlike other studies reviewed [16], the inclusion of mediator variables were theoretically informed and assessed at adequate intervals to allow temporal precedence, increasing the plausibility of interpreting effects as causal. Effects of mediator and outcome variables measured at baseline on the mediated effect and outcome were controlled for, to reduce the potential for residual confounding of the non-randomised mediator - outcome relationships in the models. In addition, the mediation analysis was conducted using data from an RCT, which further reduces the potential for confounding factors where the treatment is randomised.

Conclusion

Our results suggest that CBT treatments for IBS should target change in IBS specific cognitive and behavioural responses to symptoms as these processes lead to reduction in general anxiety and subsequent improvement in symptom severity and adjustment. These findings are in line with endogenous stress models of IBS. However, the results also indicate a mechanistic role of general

anxiety. Future studies should seek to assess whether this effect remains significant when GI specific anxiety is included in the mediation models.

Financial Support

This work was supported by the National Institute of Health Research, Health Technology Assessment (NIHR HTA) 11/69/02. Author 1 is employed by King's College London funded by the NIHR HTA grant 11/69/02/. Authors 2 and 4 are recipients of the NIHR HTA grant 11/69/02. Authors 3 and 4 are part funded by the Biomedical Research Centre for the South London and Maudsley NHS Foundation Trust and the Institute of Psychiatry. This organisation had no role in study design, collection of data, analysis, writing up, or decision to submit.

This research received no specific grant from any funding agency, commercial or not-for-profit sector

Declaration of Interest

None

Competing Interests

The authors have no competing interests to report

Ethical Standards

The authors assert that all procedures contributing to this work comply with the ethical standards of the relevant national and institutional committees on human experimentation and with the Helsinki Declaration of 1975, as revised in 2008

Acknowledgements

With thanks to the individuals who participated in the study and consented to their data being used for the present analysis. With thanks to Dr Joseph Chilcot who provided further statistical advice.

References

1. Drossman, D.A., *Functional Gastrointestinal Disorders: History, Pathophysiology, Clinical Features and Rome IV*. Gastroenterol, 2016. **150**(6): p. 1262-1279. e2. DOI: 10.1053/j.gastro.2016.02.032.
2. Kennedy, T.M. and R.H. Jones, *Epidemiology of cholecystectomy and irritable bowel syndrome in a UK population*. Br J Surg, 2000. **87**(12): p. 1658-1663. DOI: 10.1046/j.1365-2168.2000.01596.x.
3. Wilson, S., et al., *Prevalence of irritable bowel syndrome: a community survey*. Br J Gen Pract, 2004. **54**(504): p. 495-502.
4. Lovell, R.M. and A.C. Ford, *Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis*. Clin Gastroenterol Hepatol, 2012. **10**(7): p. 712-721. DOI: 10.1016/j.cgh.2012.02.029.
5. Halpert, A. and D. Drossman, *Biopsychosocial issues in irritable bowel syndrome*. J Clin Gastroenterol, 2005. **39**(8): p. 665-669.
6. Drossman, D.A., *Presidential address: Gastrointestinal illness and the biopsychosocial model*. Psychosom Med, 1998. **60**(3): p. 258-267.
7. Ford, A.C., et al., *Effect of antidepressants and psychological therapies, including hypnotherapy, in irritable bowel syndrome: systematic review and meta-analysis*. Am J Gastroenterol, 2014. **109**(9): p. 1350-1365. DOI: 10.1038/ajg.2014.148
8. Ford, A.C., et al., *Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis*. Gut, 2008. p.367-378. DOI: 10.1136/gut.2008.163162
9. Li, L., et al., *Cognitive-behavioral therapy for irritable bowel syndrome: A meta-analysis*. J Psychosom Res, 2014. **77**(1): p. 1-12. DOI: 10.1016/j.jpsychores.2014.03.006
10. Blanchard, E.B., et al., *Prediction of outcome from cognitive-behavioral treatment of irritable bowel syndrome*. Behav Res Ther, 1992. **30**(6): p. 647-650. DOI: 10.1016/0005-7967(92)90011-5
11. Craske, M.G., et al., *A cognitive-behavioral treatment for irritable bowel syndrome using interoceptive exposure to visceral sensations*. Behav Res Ther, 2011. **49**(6-7): p. 413-421. DOI: 10.1016/j.brat.2011.04.001
12. Kennedy, T., et al., *Cognitive behaviour therapy in addition to antispasmodic treatment for irritable bowel syndrome in primary care: randomised controlled trial*. BMJ, 2005. **331**(7514): p. 435-437. DOI: 10.1136/bmj.38545.505764.06
13. Lang, P.J., B.G. Melamed, and J. Hart, *A Psychophysiological Analysis of Fear Modification Using an Automated Desensitization Procedure*. J Abnorm Psychol, 1970. **76**(2): p. 220-234. DOI: Doi 10.1037/H0029875.
14. Kazdin, A.E., *Mediators and mechanisms of change in psychotherapy research*. Annu Rev Clin Psychol, 2007. **3**: p. 1-27. DOI: 10.1146/annurev.clinpsy.3.022806.091432
15. Holmes, E.A., et al., *The Lancet Psychiatry Commission on psychological treatments research in tomorrow's science*. The Lancet Psychiatry, 2018. **5**(3): p. 237-286. DOI: 10.1016/S2215-0366(17)30513-8
16. Windgassen, S., et al., *The journey between brain and gut: A systematic review of psychological mechanisms of treatment effect in irritable bowel syndrome*. Br J Health Psychol, 2017. **22**(4): p. 701-736. DOI: 10.1111/bjhp.12250.
17. Ljótsson, B., et al., *Mechanisms of change in an exposure-based treatment for irritable bowel syndrome*. J Consult Clin Psychol, 2013. **81**(6): p. 1113-1126. DOI: 10.1037/a0033439
18. Mayer, E.A., et al., *V. Stress and irritable bowel syndrome*. Am J Physiol Gastrointest Liver Physiol, 2001. **280**(4): p. 519-524. DOI: 10.1152/ajpgi.2001.280.4.G519
19. Sibelli, A., et al., *A systematic review with meta-analysis of the role of anxiety and depression in irritable bowel syndrome onset*. Psychol Med, 2016. **46**(15): p. 3065-3080.
20. Suarez, K., et al., *Psychological stress and self-reported functional gastrointestinal disorders*. J Nerv Ment Dis, 2010. **198**(3): p. 226-229. DOI: 10.1097/NMD.0b013e3181d106bc
21. Whitehead, W.E., et al., *Effects of stressful life events on bowel symptoms: subjects with irritable bowel syndrome compared with subjects without bowel dysfunction*. Gut, 1992. **33**(6): p. 825-830.

22. Reme, S.E., et al., *Mediators of change in cognitive behaviour therapy and mebeverine for irritable bowel syndrome*. Psychol Med, 2011. **41**(12): p. 2669-2679. DOI: 10.1017/S0033291711000328.
23. Garland, E.L., et al., *Therapeutic mechanisms of a mindfulness-based treatment for IBS: effects on visceral sensitivity, catastrophizing, and affective processing of pain sensations*. J Behav Med, 2012. **35**(6): p. 591-602. DOI: 10.1007/s10865-011-9391-z
24. Wolitzky-Taylor, K., et al., *Visceral sensitivity as a mediator of outcome in the treatment of irritable bowel syndrome*. Behav Res Ther, 2012. **50**(10): p. 647-650. DOI: 10.1016/j.brat.2012.05.010
25. Hesser, H., et al., *How does exposure therapy work? A comparison between generic and gastrointestinal anxiety-specific mediators in a dismantling study of exposure therapy for irritable bowel syndrome*. J Consult Clin Psychol, 2018. **86**(3): p. 254-267. DOI: 10.1037/ccp0000273
26. Kennedy, T.M., et al., *Cognitive behavioural therapy in addition to antispasmodic therapy for irritable bowel syndrome in primary care: randomised controlled trial*. Health Technol Assess, 2006. **10**(19): p. 1-67. DOI: 10.1136/bmj.38545.505764.06.
27. MacKinnon, D.P., A.J. Fairchild, and M.S. Fritz, *Mediation analysis*. Annu Rev Psychol, 2007. **58**: p. 593-614. DOI: 10.1146/annurev.psych.58.110405.085542.
28. MacKinnon, D.P., J.L. Krull, and C.M. Lockwood, *Equivalence of the mediation, confounding and suppression effect*. Prev Sci, 2000. **1**(4): p. 173-181.
29. Reme, S.E., et al., *The development of the irritable bowel syndrome-behavioral responses questionnaire*. J Psychosom Res, 2010. **69**(3): p. 319-25. DOI: 10.1016/j.jpsychores.2010.01.025.
30. Francis, C.Y., J. Morris, and P.J. Whorwell, *The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress*. Aliment Pharmacol Ther, 1997. **11**(2): p. 395-402.
31. Mundt, J.C., et al., *The Work and Social Adjustment Scale: a simple measure of impairment in functioning*. Br J Psychiatry, 2002. **180**(5): p. 461-464.
32. Toner, B.B., et al., *The development of a cognitive scale for functional bowel disorders*. Psychosom Med, 1998. **60**(4): p. 492-497.
33. Zigmond, A.S. and R.P. Snaith, *The hospital anxiety and depression scale*. Acta Psychiatr Scand, 1983. **67**(6): p. 361-370.
34. Bjelland, I., et al., *The validity of the Hospital Anxiety and Depression Scale: an updated literature review*. J Psychosom Res, 2002. **52**(2): p. 69-77. DOI: 10.1016/S0022-3999(01)00296-3
35. Helbig-Lang, S., et al., *The role of safety behaviors in exposure-based treatment for panic disorder and agoraphobia: associations to symptom severity, treatment course, and outcome*. J Anxiety Disord, 2014. **28**(8): p. 836-844. DOI: 10.1016/j.janxdis.2014.09.010.
36. Frazier, P.A., A.P. Tix, and K.E. Barron, *Testing moderator and mediator effects in counseling psychology research*. J Counsel Psychol, 2004. **51**(1): p. 115-134. DOI: 10.1037/0022-0167.51.1.115
37. MacKinnon, D.P., C.M. Lockwood, and J. Williams, *Confidence limits for the indirect effect: Distribution of the product and resampling methods*. Multivariate Behav Res, 2004. **39**(1): p. 99-128. DOI: 10.1207/s15327906mbr3901_4
38. Lubans, D.R., C. Foster, and S.J.H. Biddle, *A review of mediators of behavior in interventions to promote physical activity among children and adolescents*. Prev Med, 2008. **47**(5): p. 463-470. DOI: 10.1016/j.ypmed.2008.07.011.
39. Hayes, A.F., *Beyond Baron and Kenny: Statistical Mediation Analysis in the New Millennium*. Commun Monogr, 2009. **76**(4): p. 408-420. DOI: 10.1080/03637750903310360.
40. MacKinnon, D.P., *Introduction to statistical mediation analysis*. 2008: Routledge.
41. Baron, R.M. and D.A. Kenny, *The moderator-mediator variable distinction in social psychological research: Conceptual, strategic, and statistical considerations*. J Pers Soc Psychol, 1986. **51**(6): p. 1173-1182.
42. Kline, R.B., *Principles and practice of structural equation modeling*. 2015: Guilford publications.
43. Fritz, M.S. and D.P. MacKinnon, *Required sample size to detect the mediated effect*. Psychol Sci, 2007. **18**(3): p. 233-339. DOI: 10.1111/j.1467-9280.2007.01882.x.

44. Enders, C.K. and D.L. Bandalos, *The relative performance of full information maximum likelihood estimation for missing data in structural equation models*. Struct Equ Model, 2001. **8**(3): p. 430-457. DOI: 10.1207/S15328007SEM0803_5
45. Emsley, R., G. Dunn, and I.R. White, *Mediation and moderation of treatment effects in randomised controlled trials of complex interventions*. Stat Methods Med Res, 2010. **19**(3): p. 237-270. DOI: 10.1177/0962280209105014.
46. Goldsmith, K.A., et al., *Measurement error, time lag, unmeasured confounding: Considerations for longitudinal estimation of the effect of a mediator in randomised clinical trials*. Stat Methods Med Res, 2016: p. 1615-1633. DOI: 10.1177/0962280216666111.
47. Pickles, A., et al., *Treatment mechanism in the MRC preschool autism communication trial: implications for study design and parent-focussed therapy for children*. J Child Psychol Psychiatry, 2015. **56**(2): p. 162-170. DOI: 10.1111/jcpp.12291.
48. Dunn, G., et al., *Integrating biomarker information within trials to evaluate treatment mechanisms and efficacy for personalised medicine*. Clin Trial, 2013. **10**(5): p. 709-719. DOI: 10.1177/1740774513499651.
49. Maxwell, S.E. and D.A. Cole, *Bias in cross-sectional analyses of longitudinal mediation*. Psychol Methods, 2007. **12**(1): p. 23-44. DOI: 10.1037/1082-989X.12.1.23.
50. Maxwell, S.E., D.A. Cole, and M.A. Mitchell, *Bias in Cross-Sectional Analyses of Longitudinal Mediation: Partial and Complete Mediation Under an Autoregressive Model*. Multivariate Behav Res, 2011. **46**(5): p. 816-841. DOI: 10.1037/1082-989X.12.1.23
51. Schumacker, R.E. and R.G. Lomax, *A beginner's guide to structural equation modeling*. 2004: Psychology Press.
52. Preacher, K.J., et al., *Choosing the Optimal Number of Factors in Exploratory Factor Analysis: A Model Selection Perspective*. Multivariate Behav Res, 2013. **48**(1): p. 28-56. DOI: 10.1080/00273171.2012.710386.
53. Williams, L.J. and P.J. Holahan, *Parsimony-based fit indices for multiple-indicator models: Do they work?* Structural Equation Modeling: A Multidisciplinary Journal, 1994. **1**(2): p. 161-189.
54. Marsh, H.W. and K.-T. Hau, *Assessing goodness of fit: Is parsimony always desirable?* J Experim Edu, 1996. **64**(4): p. 364-390.
55. Preacher, K.J. and E.C. Merkle, *The problem of model selection uncertainty in structural equation modeling*. Psychol Methods, 2012. **17**(1): p. 1-14. DOI: 10.1037/a0026804.
56. Drossman, D.A., et al., *Psychosocial factors in the irritable bowel syndrome. A multivariate study of patients and nonpatients with irritable bowel syndrome*. Gastroenterol, 1988. **95**(3): p. 701-8.
57. Tack, J., et al., *Systematic review: the efficacy of treatments for irritable bowel syndrome—a European perspective*. Aliment Pharmacol Ther, 2006. **24**(2): p. 183-205. DOI: 10.1111/j.1365-2036.2006.02938.x
58. Ronnevig, M., P.O. Vandvik, and I. Bergbom, *Patients' experiences of living with irritable bowel syndrome*. J Adv Nurs, 2009. **65**(8): p. 1676-1685. DOI: 10.1111/j.1365-2648.2009.05030.x.
59. Farndale, R. and L. Roberts, *Long-term impact of irritable bowel syndrome: a qualitative study*. Prim Health Care Res Dev, 2011. **12**(1): p. 52-67. DOI: 10.1017/S1463423610000095
60. Beesdo-Baum, K., et al., *Avoidance, safety behavior, and reassurance seeking in generalized anxiety disorder*. Depress Anxiety, 2012. **29**(11): p. 948-957. DOI: 10.1002/da.21955.
61. Goetz, A.R., et al., *The functional value of preventive and restorative safety behaviors: A systematic review of the literature*. Clin Psychol Rev, 2016. **44**: p. 112-124. DOI: 10.1016/j.cpr.2015.12.005.
62. Olatunji, B.O., et al., *The effects of safety behaviors on health anxiety: an experimental investigation*. Behav Res Ther, 2011. **49**(11): p. 719-728. DOI: 10.1016/j.brat.2011.07.008
63. Labus, J.S., et al., *The Visceral Sensitivity Index: development and validation of a gastrointestinal symptom-specific anxiety scale*. Aliment Pharmacol Ther, 2004. **20**(1): p. 89-97. DOI: 10.1111/j.1365-2036.2004.02007.x.
64. Shrout, P.E. and N. Bolger, *Mediation in experimental and nonexperimental studies: new procedures and recommendations*. Psychol Methods, 2002. **7**(4): p. 422-445.
65. Polster, A., et al., *Mixture model analysis identifies irritable bowel syndrome subgroups characterised by specific profiles of gastrointestinal, extraintestinal somatic and psychological symptoms*. Aliment Pharmacol Ther, 2017. **46**(5): p. 529-539. DOI: 10.1111/apt.14207

66. Guthrie, E., et al., *Cluster analysis of symptoms and health seeking behaviour differentiates subgroups of patients with severe irritable bowel syndrome*. Gut, 2003. **52**(11):p. 1616-1622.
67. Labus, J., et al., *Randomised clinical trial: symptoms of the irritable bowel syndrome are improved by a psycho-education group intervention*. Aliment Pharmacol Ther, 2013. **37**(3):p. 304-315. DOI: 10.1111/apt.12171.

Supplementary Material

Appendix A

Figure of Three Systems Model in IBS

Appendix B

Methodology regarding selection of partial versus full mediation models

Partial versus full mediation

In mediation the total effect of an independent variable (e.g. treatment) on an outcome can be partitioned into the direct effect (path R to O, figure 1) and the indirect effect (paths from R to O via M, figure 1). The indirect effect quantifies the extent to which the treatment effect on the outcome is transmitted via the mediator (mediated effect). The direct effect quantifies the remaining direct effect of treatment on the outcome. We use the term full mediation model to describe a model explicitly assuming the direct effect is essentially equal to zero, allowing for no direct pathway between treatment and outcome, and so postulate that the full effect of the outcome is transmitted via the mediating variable (full mediation model, figure 1). Models we describe as partial mediation models allow for both direct and indirect pathways (models 1-4 and the partial mediation model, figure 1). In this latter type of model, we can assess whether mediation is partial or full; if there is full mediation, the mediated effect will be statistically significant, with a non-significant direct effect. If the mediated and direct effects are statistically significant, this indicates partial mediation.

The first four models assessed mediation via a single mediator (figure 1). In figure 1, full and partial sequential mediation models are illustrated. Each sequence (e.g. R → GI related cognitions → anxiety → outcome) was tested in the context of a partial mediation model and a full mediation model, and the best fitting model was assessed using the AIC and BIC criteria. This followed the process of the previous mediation paper (Reme, Stahl et al, 2011; Kennedy, Jones et al. 2005) and was used to determine whether the inclusion of a direct path from randomisation to outcome enhanced or detracted from the fit of the models to the data. Once a full or partial mediation model was selected, each sequence was compared using the model fit indices described above. The mediated effect of all models assessed calculated confidence intervals using bootstrap resampling with 1000 repetitions and 95% confidence interval (Chalder, Goldsmith, White, Sharpe, & Pickles, 2015; Efron & Tibshirani, 1994; Shrout & Bolger, 2002; Williams & MacKinnon, 2008)..

Chalder, T., Goldsmith, K. A., White, P. D., Sharpe, M., & Pickles, A. R. (2015). Rehabilitative therapies for chronic fatigue syndrome: a secondary mediation analysis of the PACE trial. *The Lancet Psychiatry*, 2(2), 141-152.

Efron, B., & Tibshirani, R. J. (1994). *An introduction to the bootstrap*: CRC press.

Shrout, P. E., & Bolger, N. (2002). Mediation in experimental and nonexperimental studies: New procedures and recommendations. *Psychological methods*, 7(4), 422-445.

Williams, J., & MacKinnon, D. P. (2008). Resampling and distribution of the product methods for testing indirect effects in complex models. *Structural Equation Modeling*, 15(1), 23-51.

Appendix C

A

B

Trajectory of primary outcomes

Appendix D

A.

B.

C.

D.

Best fitting models as indicated by standardised indirect effect size for symptom severity and work and social adjustment (WSA). Single headed arrows indicate hypothesized relationships between variables with standardized regression coefficients next to each path with 95% confidence intervals in brackets. Not shown in the diagrams for simplicity are the paths indicating the baseline outcome and mediator variables controlled for by including these as predictors for each dependent variable included in the model.

Appendix E

Comparison of model fit indices for full versus partial mediation models of sequences

	Full/Partial Model	RMSEA [90% CI]	CFI	TLI	AIC	BIC	χ^2 GOF	Indirect effect <i>p</i>
Symptom Severity								
R→C→A→IBS-SS	Full	0.070 [0, 0.14]	0.981	0.952	2111.6	2198.5	$\chi^2(6)=10.38$, p=.11	.006
	Partial	0.083 [0, 0.16]	0.977	0.932	2113.3	2203.2	$\chi^2(5)=10.15$, p=.07	.006
R→A→C→IBS-SS	Full	0.102 [0, 0.17]	0.949	0.872	2174.0	2260.9	$\chi^2(6)=15.20$, p=.02	.01
	Partial	0.117 [0.05, 0.19]	0.944	0.831	2176.0	2266.0	$\chi^2(5)=15.16$, p=.01	.01
R→SB→A→IBS-SS	Full	0.08 [0, 0.15]	0.976	0.939	2218.9	2305.8	$\chi^2(6)=11.17$, p=.08	.046
	Partial	0.09 [0, 0.16]	0.975	0.924	2220.1	2310.0	$\chi^2(5)=10.42$, p=.06	.046
R→A→SB→IBS-SS	Full	0.121 [0.06, 0.18]	0.943	0.898	2202.0	2289.0	$\chi^2(6)=18.91$, p=.004	.014
	Partial	0.119 [0.05, 0.19]	0.954	0.862	2200.6	2290.5	$\chi^2(6)=15.14$, p=.009	.014
Work and Social Adjustment								
R→C→A→WSA	Full	0.151 [0.10, 0.21]	0.929	0.822	1974.8	2061.8	$\chi^2(6)=26.20$, p<.001	.002
	Partial	0.166 [0.11, 0.23]	0.928	0.785	1976.0	2065.9	$\chi^2(5)=25.33$, p<.001	.002
R→A→C→WSA	Full	0.160 [0.10, 0.22]	0.911	0.777	2018.6	2105.5	$\chi^2(6)=28.63$, p<.001	.003
	Partial	0.177 [0.12, 0.24]	0.908	0.724	2020.2	2110.2	$\chi^2(5)=28.29$, p<.001	.003
R→SB→A→WSA	Full	0.096 [0.03, 0.16]	0.966	0.914	2146.3	2233.2	$\chi^2(6)=14.18$, p=.03	.03
	Partial	0.105 [0.04, 0.18]	0.966	0.898	2147.2	2237.2	$\chi^2(5)=13.10$, p=.02	.03
R→A→SB→WSA	Full	0.115 [0.06, 0.18]	0.954	0.884	2125.8	2212.7	$\chi^2(6)=17.66$, p=.007	.02
	Partial	0.131 [0.07, 0.20]	0.950	0.849	2127.8	2217.7	$\chi^2(6)=17.66$, p=.003	.02

Rows in bold indicate best fitting model; RMSEA, root mean square error of approximation; CFI, comparative fit index, TLI, Tucker-Lewis Index; AIC, Akaike's Information Criterion; BCC, Brown-Cudeck criteria; χ^2 GOF, Chi square goodness of fit. R, randomisation; A, general anxiety; C, GI related cognitions; SB, GI safety behaviours; WSA, work and social adjustment; SS, symptom severity

Highlights

- Change in gastrointestinal cognitions, gastrointestinal safety behaviours and general anxiety mediate treatment effect of cognitive behavioural therapy on the outcomes of symptom severity and work and social adjustment in IBS
- Change in gastrointestinal cognitions precede reduction in general anxiety
- Change in gastrointestinal safety behaviours precede reduction in general anxiety
- Change in gastrointestinal avoidance behaviour was not a mediator of treatment effect
- Psychological treatments in IBS should target gastrointestinal specific responses for change in IBS